

# **The Ultra Specific Antibodies**

Validated against > 17,000 Human Antigens

Confidence in your Antibody Accuracy in your Results



### **Trust Your IHC Antibodies**

High specificity is the prerequisite for any antibody used in diagnostic and therapeutic applications. Antibody cross-reactivity will create unexpected side effects or false diagnostic reports for clinicians. Research data from various groups have shown that some monoclonal antibodies on the market are not mono-specific. Similar epitopes are sometimes found across multiple unrelated proteins.

## Antibody Validation Technology

Protein microarray technology can evaluate antibody specificity at the proteome-wide level. With the world's most extensive collection of overexpression antigen standards, OriGene developed a high-density protein microarray chip for antibody validation. This protein chip is spotted with over 17,000 unique overexpression proteins in duplicate on a single nitrocellulose-coated glass slide. OriGene's protein microarray technology has been used to validate the specificity of an existing ERCC1 diagnostic monoclonal antibody, and has been applied as a screening method to identify the most specific TrueMAB<sup>™</sup> monoclonal antibody for ERCC1.





The excision repair cross-complementation group 1 (ERCC1)protein is an important biomarker for clinicians to predict whether certain patient populations with non-small cell lung carcinoma (NSCLC) will respond to cisplatin chemotherapy. As such, developing highly specific immunohistochemistry- validated monoclonal antibodies for this diagnostic test is critical. Several publications reveal that 8F1, the most commonly used antibody clone for ERCC1, exhibits cross-reactivity to an unknown protein in ERCC1 deficient cell lines. Using OriGene's protein microarray technology, the corresponding cross-reactive binding protein for the 8F1 antibody was identified (Figure 1a). This technology also enabled OriGeneto develop the most specific UltraMABTM monoclonal antibody for ERCC1 (clone 4F9) (Figure 1b). This data was further confirmed by Western blot analysis using the KO lysate and in IHC by testing on normal tissue (Figure 2) and cancer tissue sections (Figure 3).



#### Figure 1. Specificity test results with OriGene's 10K protein microarray chip.

ERCC1 antibodies, 8F1 and UltraMAB 4F9, were used to immunostain a 10K protein microarray chip. 8F1 demonstrates recognition against two ERCC1 variants in subarrays 1 and 2 as well as a third protein in subarray 3, labeled as "Protein 8F1" (a). 4F9 specifically recognizes two ERCC1 variants in subarrays 1 and 2 with no additional proteins in subarray 3 (b).



**Figure 2.** IHC staining of FFPE normal adjacent lung from tumor specimen using ERCC1 UltraMAB (clone 4F9, 1ug/ml).

#### **Reference:**

1. D. Ma, et al., Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology. BMC Biotechnology. 2012 Nov 21;12(1):88



**Figure 3.** IHC staining of FFPE endometrial carcinoma using ERCC1 UltraMAB (clone 4F9, 1ug/ml).



Human epidermal growth factor receptor 2 (HER2), also known as ERBB2, CD340, or p185 is a member of the epidermal growth factor receptor (EGFR/ErbB) family. Amplification or overexpression of this gene has been shown to play an essential role in the pathogenesis and progression of certain aggressive types of breast cancer and gastric cancer and it has evolved to become an important biomarker and target of therapy for the disease.

A semi-quantitative immunohistochemical assay using an anti-HER2 antibody is applied to determine HER2 protein overexpression in breast cancer tissues. The specificity of the HER2 antibody (e.g. Clone 4B5) is critical because the test results will help oncologists decide whether a patient should receive Herceptin™ treatment. Using OriGene's high-density protein microarray, we have revealed that antibody 4B5 is not specific to HER2 protein. As shown in Figure 1, this antibody also reacts with ZSCAN1B and HER4 (ERBB4). In contrast, HER2 UltraMAB™ (Clone UMAB36) developed by OriGene only recognizes HER2 protein and is thus specific. The performance of HER2 UltraMAB™ is also validated with IHC staining of breast cancer tissues (Figure 2).



**Figure 1. ERBB2 antibody specificity test results with OriGene's 10K protein microarray chip.** Antibody 4B5 (left) and OriGene's HER2 UltraMAB UM500036<sup>1</sup> (right). The commonly used diagnostic antibody 4B5 recognizes not only HER2 (ERBB2) protein, but also HER4 (ERBB4) and an unrelated protein ZSCAN18. OriGene's anti-HER2 UltraMAB recognizes only HER2 (ERBB2) protein.



**Figure 2.** Immunohistochemical staining of paraffin-embedded Carcinoma of breast tissue (HER2+++) using anti-ERBB2 mouse monoclonal antibody. (Clone UMAB36, Dilution 1:100)

<sup>1</sup>UM500036 is not available anymore, the alternative antibody is <u>UM570035</u>.



#### The Ultra Specific Antibody with Outstanding Performance

In addition to speficity, performance is crucial to antibodies used for diagnostic and therapeutic applications. To ensure superior performance, OriGene validates every UltraMAB<sup>™</sup> monoclonal antibody according to the scientific findings and the medical records of related diseases. The validated applications include WB, IHC staining with over 25 types of normal and cancer human tissues, IF/ICC, and FACS.

UltraMAB<sup>™</sup> Development Flowchart



#### UltraMAB<sup>™</sup> Antibody Selection





ERBB2





OriGene has over 160 different targets as ultra-specific antibodies available. Find the right solution for your research <u>here</u> or access the product overview by scanning the qr-code.







# **Contact Us!**

#### North America:

OriGene Technology Inc. 9620 Medical Center Drive, Suite 200 Rockville, MD 20850 301.340.3188 productorders@origene.com custsupport@origene.com www.origene.com

#### **European Union:**

OriGene Technologies GmbH Schillerstr. 5 32052 Herford Germany +49-5221-34606-0 ordering-de@origene.com www.origene.com

